Form 8-K - Current report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 4, 2025

CHROMADEX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

001-37752

26-2940963

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

10900 Wilshire Blvd. Suite 600, Los Angeles, California 90024

(Address of principal executive offices, including zip code)

(310) 388-6706

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	CDXC	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On March 4, 2025, ChromaDex Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and the year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, unless expressly incorporated by specific reference in such filing.

Item 7.01. Regulation FD Disclosure.

On March 4, 2025, the Company released a corporate presentation which it made available on its website. A copy of the corporate presentation is attached hereto as Exhibit 99.2.

The information in this Item 7.01, including Exhibit 99.2, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, unless expressly incorporated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit Number						Description

99.1						Press Release dated March 4, 2025
99.2						Earnings Presentation of ChromaDex Corporation
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	CHROMADEX CORPORATION

Dated: March 4, 2025	By:	/s/ Robert Fried
		Name: Robert Fried
		Chief Executive Officer

EXHIBIT 99.1

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

Full year net sales of $99.6 million, up 19% from the prior year, gross margin of 61.8%, net income of $8.6 million, Adjusted EBITDA of $8.5 million, and $12.1 million in operating cash flows. Ended the year with $44.7 million in cash and no debt. Fourth quarter net sales of $29.1 million, up 37% from the prior year, gross margin of 62.5%, and net income of $7.2 million.

LOS ANGELES, CA - March 4, 2025 - ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results.

Fourth Quarter 2024

•Total net sales of $29.1 million, with $22.7 million from Tru Niagen®, up 37% and 29%, respectively, from the prior year quarter.

•Posted strong gross margin of 62.5%, up 150 basis points from 61.0% in the prior year quarter.

•General and administrative expense decreased $4.4 million, which includes a $3.5 million reversal of previously accrued royalties and license maintenance fees and a $1.3 million recovery of credit losses related to the legal settlement with Elysium Health, LLC.

•Delivered record net income of $7.2 million, a $7.1 million improvement from $0.1 million in the prior year quarter.

•Basic and diluted earnings per share was $0.09, a significant improvement from approximately break-even earnings per share in the prior year quarter for each.

•Adjusted EBITDA, a non-GAAP measure, was $3.4 million, a $2.1 million improvement from the prior year quarter.

Full Year 2024 and Highlights

•Delivered on latest financial outlook, exceeding targets across all key performance metrics, reinforcing our strong execution and commitment to driving shareholder value by focusing on both top and bottom-line growth.

•Total net sales of $99.6 million, up 19%, with $76.8 million from Tru Niagen® and $19.2 million from Niagen ingredients, up 10% and 82%, respectively, year-over-year.

•Gross margin of 61.8%, an improvement of 100 basis points from 60.8% in the prior year.

•Selling and marketing expense as a percentage of net sales improved 200 basis points year-over-year.

•General and administrative expense decreased $6.6 million year-over-year, which includes a $3.5 million reversal of previously accrued royalties and license maintenance fees and a $1.3 million recovery of credit losses related to the legal settlement with Elysium Health, LLC.

•Achieved net income of $8.6 million, an improvement of $13.5 million, from a net loss of $4.9 million in the prior year.

•Basic and diluted earnings per share was $0.11, significantly improving from $0.07 loss per share in the prior year for each.

•Adjusted EBITDA, a non-GAAP measure, was $8.5 million, a $6.6 million improvement year-over-year.

•Positive operating cash flows of $12.1 million, ending the year with $44.7 million in cash and no debt.

•In 2024, ChromaDex launched Niagen Plus, a product line featuring pharmaceutical-grade Niagen®. These Niagen Plus products, including Niagen IV and injectables, are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively by prescription at participating wellness clinics. As of today, Niagen Plus products are available at over 475 leading wellness clinics in the U.S.

•In 2024, ChromaDex achieved key regulatory milestones, receiving Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA for NR. The Company is actively engaged with the FDA to address regulatory considerations and advance its Investigational New Drug (IND) application for the treatment of Ataxia Telangiectasia (AT), a rare and progressive childhood disorder impacting neurological and immune function.

“ChromaDex proudly delivered a record breaking $29.1 million in net sales for the fourth quarter of 2024, up 37% from the prior year quarter, with $7.2 million in net income. This contributed to full year net sales of $99.6 million, a 19% increase year-over-year, along with $8.6 million in net income and $12.1 million in operating cash flow,” said Rob Fried, ChromaDex Chief Executive Officer. “With $44.7 million in cash and no debt, we believe we are in a strong position to navigate challenges, seize opportunities, and drive continued success in 2025 and beyond.”

Results of operations for the three months ended December 31, 2024 compared to the prior year quarter

Net Sales for ChromaDex increased 37%, or $7.9 million, to $29.1 million. Net sales growth was primarily driven by a $5.0 million increase in Tru Niagen® sales (primarily from e-commerce) and $2.9 million higher ingredient sales (primarily from food-grade Niagen).

Gross Margin improved 150 basis points to 62.5% primarily due to changes in product and business mix and improvements in labor and overhead utilization rates with higher sales.

Operating Expense decreased 15%, or $2.0 million, to $11.1 million.

•General and administrative (G&A) expense decreased by $4.4 million, driven by lower royalty expenses, including a $3.5 million reversal of previously accrued royalties and license maintenance fees, and lower credit loss expense, including a $1.3 million recovery of credit losses related to a legal settlement.

•These decreases were offset by increases in selling and marketing (S&M) expense and research and development (R&D) expense of $2.2 million and $0.2 million, respectively.

Net Income was $7.2 million compared to $0.1 million for the fourth quarter of 2023.

Earnings Per Share for basic and diluted was $0.09, compared to approximately break-even for both metrics in the prior year quarter.

Adjusted EBITDA, a non-GAAP measure, was $3.4 million, an increase of $2.1 million from $1.2 million for the fourth quarter of 2023. See “Reconciliation of Non-GAAP Financial Measures” for a reconciliation of non-GAAP Adjusted EBITDA to net income (loss), the most directly comparable GAAP measure.

Results of operations for the year ended December 31, 2024 compared to the prior year

Net Sales for ChromaDex increased 19%, or $16.0 million, to $99.6 million. Net sales growth was largely driven by $7.2 million in higher sales of Tru Niagen® (primarily from e-commerce) and $8.7 million higher ingredient sales (primarily from food-grade Niagen).

Gross Margin improved 100 basis points to 61.8% due to improvements in labor and overhead utilization rates with higher sales.

Operating Expense decreased 4%, or $2.5 million, to $53.9 million.

•G&A expense decreased $6.6 million, driven by lower royalty expenses, including a $3.5 million reversal of previously accrued royalties and license maintenance fees, lower credit loss expense, including a $1.3 million recovery of credit losses related to a legal settlement, and lower executive and administrative wages.

•These decreases were offset by increases in S&M expense of $3.0 million and R&D expense of $1.1 million.

Net Income was $8.6 million compared to a net loss of $4.9 million for fiscal year 2023.

Earnings Per Share for basic and diluted was $0.11, compared to a $0.07 loss per share for both metrics in the prior year.

Adjusted EBITDA, a non-GAAP measure, was $8.5 million, an increase of $6.6 million, compared $1.9 million for fiscal year 2023. See “Reconciliation of Non-GAAP Financial Measures” for a reconciliation of non-GAAP Adjusted EBITDA to net income (loss), the most directly comparable GAAP measure.

Cash Flow from Operating Activities had a net cash inflow of $12.1 million compared to $7.1 million for fiscal year 2023 largely due to improvements in net income largely offset by non-cash items and changes in working capital.

Cash and cash equivalents totaled $44.7 million at December 31, 2024 compared to $27.3 million at December 31, 2023.

2025 Outlook

For the full year 2025, the Company expects to build on the momentum established in 2024, projecting approximately 18% year-over-year revenue growth. This outlook reflects anticipated continued expansion of the Company's e-commerce business, growth through established partnerships, and increased revenue from the pharmaceutical-grade Niagen® ingredient business. Gross margin is expected to improve slightly year-over-year, driven by ongoing supply chain optimization efforts, cost savings initiatives, and overall business scale. Selling and marketing expenses are projected to increase in absolute dollars but remain stable as a percentage of net sales, as the Company continues to make strategic investments to enhance brand awareness and support its various business channels while maintaining efficiency. The Company also remains committed to maintaining a steady investment in research and development throughout 2025 to drive future innovation. General and administrative expenses are expected to increase by approximately $5.0 to $6.0 million, primarily due to investments in business growth and the absence of a $3.5 million royalty expense reversal that occurred in 2024.

Investor Conference Call

A live webcast will be held Tuesday, March 4, 2025 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss ChromaDex’s fourth quarter and fiscal year 2024 financial results and provide a general business update.

To listen to the webcast, or to view the earnings press release and its accompanying financial exhibits, please visit the Investor Relations section of ChromaDex’s website at www.ChromaDex.com. The toll-free dial-in information for this call is 1-888-596-4144 with Conference ID: 8584242.

The webcast will be recorded, and will be available for replay via the website from 7:30 p.m. Eastern time on March 4, 2025 to 11:59 p.m. Eastern time on March 13, 2025. The replay of the call can also be accessed by dialing 1-800-770-2030, using the Replay ID: 8584242.

Important Note on Forward Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes” “seeks,” “may,” “will,” “should,” “could,” “predicts,” “projects,” “continue,” “would” or the negative of such terms or other similar expressions. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the quotation from ChromaDex’s Chief Executive Officer, statements related to the Company’s 2025 financial outlook including but not limited to revenue growth, gross margin, expenses, investment plans, and the statements regarding Niagen Plus.

Risks that contribute to the uncertain nature of the forward-looking statements include: inflationary conditions and adverse economic conditions; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of conducting business in China; including unanticipated developments in and risks related to the Company’s ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner; the Company’s ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to compound and distribute pharmaceutical-grade Niagen to clinics; the Company’s ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company’s ability to maintain and enforce the Company’s existing intellectual property and obtain new patents; whether the potential benefits of NRC can be further supported; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities; and the risks and uncertainties associated with our business and financial condition in general, described in our filings with the Securities and Exchange Commission (SEC), including, without limitation, our most recent Annual Report on Form 10-K as filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

About ChromaDex:

ChromaDex Corporation is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. NAD+ levels in humans have been shown to decline with age, among other factors, and may be increased through supplementation with NAD+ precursors. ChromaDex is the innovator behind the NAD+ precursor nicotinamide riboside chloride (“NRC” commonly referred to as “NR”), commercialized as the flagship ingredient Niagen®, available in both food and pharmaceutical grades. Nicotinamide riboside chloride and other NAD+ precursors are protected by ChromaDex’s patent portfolio.

The Company delivers Niagen® as the sole or principal dietary ingredient in its consumer product line Tru Niagen® available at www.TruNiagen.com and through partnerships with global retailers and distributors. The Company also develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen® and pharmaceutical-grade Niagen®, and supplies these ingredients as raw materials to the manufacturers of consumer products and U.S. FDA-registered 503B outsourcing facilities, respectively. The Company further offers natural product fine chemicals, known as phytochemicals, and related research and development services. Follow us on X (formerly Twitter) @ChromaDex and Instagram @TruNiagen and subscribe to our latest news via our website accessible at www.ChromaDex.com to which ChromaDex regularly posts copies of its press releases as well as additional updates and financial information about the Company.

Contacts:


Investor Relations
Ben Shamsian
Lytham Partners
+1 (646) 829-9701
Shamsian@LythamPartners.com



Media Relations
Kendall Knysch
Director of Media Relations
+1 (310) 388-6706 Ext. 689
Kendall.Knysch@ChromaDex.com

ChromaDex Corporation and Subsidiaries

Consolidated Statements of Operations


	Three Months Ended December 31,				Year Ended December 31,
	2024		2023		2024		2023
(In thousands, except per share data)
Sales, net	$	29,125	$	21,196	$	99,597	$	83,570
Cost of sales	10,928		8,259		38,011		32,790
Gross profit	18,197		12,937		61,586		50,780
Operating expenses:
Sales and marketing	8,716		6,520		29,469		26,438
Research and development	1,315		1,159		6,016		4,958
General and administrative	1,055		5,426		18,375		24,983
Total operating expenses	11,086		13,105		53,860		56,379
Operating income (loss)	7,111		(168)		7,726		(5,599)


Interest income, net	373		282		1,129		661

Income before provision for income taxes	$	7,484	$	114	$	8,855	$	(4,938)
Provision for income taxes	$	305	$	—	$	305	$	—
Net income (loss)	$	7,179	$	114	$	8,550	$	(4,938)

Net income (loss) per share attributable to common stockholders:
Basic	$	0.09	$	—	$	0.11	$	(0.07)
Diluted	$	0.09	$	—	$	0.11	$	(0.07)

Weighted average common shares outstanding:
Basic	76,945		75,135		75,929		74,985
Diluted	81,681		75,122		78,125		74,985

ChromaDex Corporation and Subsidiaries

Consolidated Balance Sheets


	December 31,
(In thousands except par values, unless otherwise indicated)	2024		2023
Assets
Current assets:
Cash and cash equivalents, including restricted cash of $152 for both periods presented	$	44,660	$	27,325
Trade receivables, net of allowances of $95 and $68, respectively; including receivables from Related Party of zero and $2.8 million, respectively.	7,768		5,234
Inventories	9,192		14,525
Prepaid expenses and other assets	2,482		2,450
Total current assets	64,102		49,534

Leasehold improvements and equipment, net	1,719		2,137
Intangible assets, net	359		510
Right-of-use assets	1,730		2,400
Other long-term assets	368		383
Total assets	$	68,278	$	54,964

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	8,526	$	10,232
Accrued expenses	7,817		9,493
Current maturities of operating lease obligations	982		691
Current maturities of finance lease obligations	12		11
Customer deposits	611		195
Total current liabilities	17,948		20,622
Deferred revenue	2,579		3,311
Operating lease obligations, less current maturities	1,657		2,563
Finance lease obligations, less current maturities	—		12










Total stockholders’ equity	46,094		28,456
Total liabilities and stockholders’ equity	$	68,278	$	54,964

ChromaDex Corporation and Subsidiaries

Consolidated Statements of Cash Flows

The following table presents selected data from our consolidated statements of cash flows for the years presented:


	Year Ended December 31,
(In thousands)	2024		2023
Net cash provided by / (used in):
Operating activities	$	12,109	$	7,117
Investing activities	(143)		(143)
Financing activities	5,369		(90)
Net increase (decrease) in cash and cash equivalents	17,335		6,884
Cash and cash equivalents beginning of year	27,325		20,441
Cash and cash equivalents at end of year	$	44,660	$	27,325

ChromaDex Corporation and Subsidiaries

Unaudited Reconciliation of Non-GAAP Financial Measures


Reconciliation of Net Income (Loss) to Adjusted EBITDA

	Three Months Ended								Full Year 2024
(In thousands)	Q1 2024		Q2 2024		Q3 2024		Q4 2024
Net income (loss), as reported	$	(492)	$	(15)	$	1,878	$	7,179	$	8,550
Adjustments:
Interest income, net	(239)		(241)		(276)		(373)		(1,129)
Provision for income taxes	—		—		—		305		305
Depreciation	178		170		164		151		663
Amortization of intangibles	38		37		38		38		151
Noncash lease expense	174		163		164		169		670
Share-based compensation	984		1,185		735		752		3,656
Severance and restructuring	27		276		185		(4)		484
Reversal of previously accrued royalties and license maintenance fees (1)	—		—		—		(3,521)		(3,521)
Recovery of credit losses related to legal settlement (2)	—		—		—		(1,325)		(1,325)
Adjusted EBITDA	$	670	$	1,575	$	2,888	$	3,371	$	8,504

(1) The reversal previously accrued royalties and license maintenance fees is related to a supplemental agreement with Dartmouth, which waived certain obligations under the exclusive license agreements.

(2) The recovery of credit losses relates to the legal settlement with Elysium Health, LLC in 2024, reversing a bad debt write-off from 2019.


Reconciliation of Net Income (Loss) to Adjusted EBITDA

	Three Months Ended								Full Year 2023
(In thousands)	Q1 2023		Q2 2023		Q3 2023		Q4 2023
Net income (loss), as reported	$	(1,902)	$	(2,191)	$	(959)	$	114	$	(4,938)
Adjustments:
Interest income, net	(66)		(125)		(188)		(282)		(661)
Depreciation	228		232		233		177		870
Amortization of intangibles	41		39		39		39		158
Noncash lease expense	171		173		176		157		677
Share-based compensation	1,273		1,324		1,117		1,037		4,751
Severance and restructuring	186		766		86		5		1,043

Adjusted EBITDA	$	(69)	$	218	$	504	$	1,247	$	1,900

Non-GAAP Financial Information:

To supplement ChromaDex’s unaudited financial data presented in accordance with generally accepted accounting principles (GAAP), the Company has presented Adjusted EBITDA, a non-GAAP financial measure. ChromaDex believes the presentation of such non-GAAP financial measure provides important supplemental information to management and investors and enhances the overall understanding of the Company’s historical and current financial operating performance. The Company believes disclosure of the non-GAAP financial measure has substance because the excluded expenses are infrequent in nature, are variable in nature or do not represent current cash expenditures. Further, such non-GAAP financial measure is among the indicators the Company uses as a basis for evaluating the Company’s financial performance as well as for planning and forecasting purposes. Accordingly, disclosure of this non-GAAP financial measure provides investors with the same information that management uses to understand the Company’s economic performance year-over-year.

Adjusted EBITDA is defined as net income before (a) interest, (b) provision for income taxes, (c) depreciation, (d) amortization, (e) non-cash share-based compensation costs, (f) severance and restructuring expense and (g) other infrequent items, including the reversal of previously accrued royalties and license maintenance fees, and the recovery of previously recognized credit losses from a legal settlement. While ChromaDex believes that this non-GAAP financial measure provides useful supplemental information to investors, there are limitations associated with the use of such measure. This measure is not prepared in accordance with GAAP and may not be directly comparable to similarly titled measures of other companies due to potential differences in the method of calculation. Management compensates for these limitations by relying primarily on the Company’s GAAP results and by using Adjusted EBITDA only supplementally and by reviewing the reconciliation of the non-GAAP financial measure to its most comparable GAAP financial measure.

Non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States. The Company’s non-GAAP financial measure is not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with the company’s consolidated financial statements prepared in accordance with GAAP.

ChromaDex Earnings Conference Call Fourth Quarter 2024 Nasdaq: CDXC | March 4, 2025

2 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect the current view about future events. Statements that are not historical in nature, such as 2025 financial outlook, and which may be identified by the use of words like “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes,” “seeks,” “may,” “will,” “should,” “could,” “predicts,” “projects,” “continue,” “would” or the negative of these terms and other words of similar meaning, are forward-looking statements. Such statements include, but are not limited to, statements contained in this presentation relating to our expected sales, cash flows, planned investments, and financial performance, business, business strategy, expansion, growth, key drivers (including cost savings and increased investments), products and services we offer and their impact on our performance or products and services we may offer in the future and the timing of their development, sales and marketing strategy and capital outlook. Forward-looking statements are based on management’s current expectations and assumptions regarding our business, the economy and other future conditions and are subject to inherent risks, uncertainties and changes of circumstances that are difficult to predict and may cause actual results to differ materially from those contemplated or expressed. We caution you therefore against relying on any of these forward-looking statements. These risks and uncertainties include those risk factors discussed in Part I, “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities Exchange Commission (the “Commission”), and in subsequent filings with the Commission. Any forward-looking statements are qualified in their entirety by reference to the factors discussed in these filings with the Commission. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Important factors that could cause actual results to differ materially from those in the forward looking statements include but are not limited to: inflationary conditions and adverse economic conditions; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of conducting business in China; including unanticipated developments in and risks related to the Company’s ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner; the Company’s ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to compound and distribute pharmaceutical-grade Niagen to clinics; the Company’s ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company’s ability to maintain and enforce the Company’s existing intellectual property and obtain new patents; whether the potential benefits of NRC can be further supported; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities; and the risks and uncertainties associated with our business and financial condition in general. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results. About Non-GAAP Financial Measures ChromaDex’s non-GAAP financial measure, Adjusted EBITDA, is defined as net income before interest, provision for income taxes, depreciation, amortization, non-cash share-based compensation costs, severance and restructuring expense and other infrequent items, including the reversal of previously accrued royalties and license maintenance fees, and the recovery of previously recognized credit losses from a legal settlement. ChromaDex used this non-GAAP measures when evaluating its financial results as well as for internal resource management, planning and forecasting purposes. This non-GAAP measure should not be viewed in isolation from or as a substitute for ChromaDex’s financial results in accordance with GAAP. Reconciliation of this non-GAAP measure to the most directly comparable GAAP measure is attached to this presentation. FDA Disclaimer Statements made in this presentation have not been evaluated by the Food and Drug Administration. ChromaDex products are not intended to diagnose, treat, cure, or prevent any disease. The statements in this presentation are for investor relations and educational purposes only and not intended for consumers or vendors. SAFE HARBOR STATEMENT

3 Q4 2024 & Recent Highlights (1) See slide 11 for the non-GAAP reconciliation Delivered record-breaking financial performance in 2024 through strategic initiatives while strengthening our foundation for sustained growth, positioning us for continued success in 2025 and beyond. Fourth Quarter 2024 • Total company and Tru Niagen® net sales: $29.1 million and $22.7 million, up 37% and 29% YoY, respectively. • Total Niagen® ingredient sales: $5.3 million, up 96% YoY. • Gross margin: 62.5%, up 150 basis points YoY. • Net income: $7.2 million, up $7.1 million YoY. • Adjusted EBITDA(1): $3.4 million, nearly tripling, from $1.2 million in Q4 2023. Full Year 2024 • Grew net sales 19% YoY, alongside strong 61.8% gross margins and increased efficiencies across the P&L. • Net income of $8.6 million, or $0.11 earnings per share, (vs net loss of $4.9 million, or $0.07 loss per share) • Operating cash flows: $12.1 million, ending the year with $44.7 million in cash and no debt. • Adjusted EBITDA(1): $8.5 million, up from $1.9 million in FY 2023. • Exceeded financial outlook, outperforming targets across all key performance metrics 2025 Outlook • Introduced 2025 financial outlook: expect continued revenue growth around 18% year over year, with modest P&L efficiencies with focused investments in innovation and brand awareness to build upon our position as a leader in the NAD+ market.

4 Management Team Rob Fried Chief Executive Officer E-commerce & entertainment industry executive Savoy Pictures, Columbia Pictures, Fried Films, FeeIn, WHN, Healthspan Research Andrew Shao SVP, Global Regulatory & Scientific Affairs Over two decades of global nutrition industry experience at Amway, Herbalife Nutrition, and the Council for Responsible Nutrition Ozan Pamir Chief Financial Officer Over a decade of capital markets and public company experience in the life sciences industry CFA Charterholder Carlos Lopez SVP, General Counsel Over a decade of experience in the dietary supplements industry. Previously served as VP, General Counsel at The Vitamin Shoppe and board member of The Natural Products Association Michiko Kelley Chief Marketing Officer Over two decades of experience in marketing strategy, marketing operation, product management, and leadership at Dexcom and Sony Electronics

Financial Highlights

6 Q4 2024 Net Sales Mix E-commerce 63% Watson's & Other B2B 20% Food-grade Niagen® 13% Analytical Reference Standards & Services 3% Other Ingredients 1% Q4 2023Q4 2024 • Tru Niagen® net sales decreased to 78% of net sales in Q4 2024 compared to 83% in Q4 2023(1) • Niagen®-related net sales remained steady at 96% of net sales for Q4 2024 and Q4 2023(2) E-commerce 59% Watson's & Other B2B 19% Food-grade Niagen® 15% Pharmaceutical-grade Niagen® 3% Analytical Reference Standards & Services 3% Other Ingredients 1% $ 29.1 MM Higher mix of Niagen® Ingredient sales in Q4 2024 compared to the prior year, including sales of recently launched pharmaceutical-grade Niagen®. (1) Tru Niagen® net sales include E-commerce, Watson’s/Other B2B (2) Niagen®-related sales include Tru Niagen® and Niagen® ingredient $ 21.2 MM

7 Q4 2024 Net Sales Q4 2024 Net Sales ($ in millions) $22.7 17.3 5.4 4.5 0.8 0.7 0.4 E-commerce Watson's & Other B2B Food-grade Niagen® Pharmaceutical-grade Niagen® Analytical Reference Standards & Services Other Ingredients Q4 2024 total net sales up 37% year-over-year driven by strong growth in E-commerce sales, along with growth in all other sales channels. YoY % (vs Q4 2023) +30% +26% +67% +2% N/A +37%Total +157%

58.0 18.8 17.5 1.7 3.0 0.6 E-commerce Watson's & Other B2B Food-grade Niagen® Pharmaceutical-grade Niagen® Analytical Reference Standards & Services Other Ingredients 8 Full Year 2024 Net Sales FY 2024 Net Sales ($ in millions) Total +19% +13% +3% +66% +4% (2)% YoY % (vs FY 2023) $76.8 2024 total net sales increased 19% year-over-year primarily driven by growth in E-commerce business and strong Niagen® Ingredient sales from new and established partners. N/A

9 2023 – 2024 Net Sales Summary ($ in millions) 2024 2023 Description Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Ecommerce 12.9 13.0 14.8 17.3 58.0 12.2 13.0 12.7 13.3 51.2 Watsons & Other B2B 4.5 5.6 3.3 5.4 18.8 5.4 3.9 4.7 4.3 18.3 Total TRU NIAGEN 17.4 18.6 18.1 22.7 76.8 17.6 16.9 17.4 17.6 69.5 Food-grade NIAGEN 4.1 3.1 5.8 4.5 17.5 3.9 2.5 1.4 2.7 10.6 Pharmaceutical-grade NIAGEN 0.0 0.0 0.9 0.8 1.7 0.0 0.0 0.0 0.0 0.0 Total NIAGEN Ingredient 4.1 3.1 6.7 5.3 19.2 3.9 2.5 1.4 2.7 10.6 NIAGEN Related Revenues 21.5 21.7 24.8 28.0 96.0 21.5 19.4 18.8 20.3 80.0 Other Ingredients 0.0 0.2 0.0 0.4 0.6 0.2 0.2 0.0 0.2 0.6 Analytical Reference Standards & Services 0.7 0.8 0.8 0.7 3.0 0.8 0.7 0.7 0.7 2.9 Total Net Sales 22.2 22.7 25.6 29.1 99.6 22.5 20.3 19.5 21.2 83.5 TRU NIAGEN as % of Total Net Sales 78 % 82 % 71 % 78 % 77 % 78 % 83 % 89 % 83 % 83 % NIAGEN Related Revenues as % of Total Net Sales 97 % 96 % 97 % 96 % 96 % 95 % 95 % 97 % 96 % 96 % YOY Growth Rate - Net Sales Total Company (2) % 12 % 31 % 37 % 19 % 31 % 21 % 14 % 1 % 16 % NIAGEN Related — % 12 % 32 % 38 % 20 % 34 % 21 % 15 % 2 % 17 % Total TRU NIAGEN (2) % 10 % 4 % 29 % 10 % 18 % 16 % 19 % 9 % 16 %

10 Q4 2024 vs Q4 2023 Key P&L Metrics (in thousands) Q4 2024 Q4 2023 Notes Net Sales $29,125 $21,196 Tru Niagen® sales increased by 29%, while Niagen ingredient sales grew by 96%, driven by strong Ecommerce performance, increased demand from food-grade ingredient partners, and the launch of pharmaceutical-grade ingredients. Gross Profit % of Net Sales 18,197 62.5% 12,937 61.0% Up 150 bps driven by a shift in business and product mix, and improvements in labor and overhead utilization rates with higher sales Sales and Marketing % of Net Sales 8,716 29.9% 6,520 30.8% Reflects increased marketing investments, with improved efficiencies driven by higher ingredient sales, which grow through partnerships rather than direct consumer marketing spend Research and Development 1,315 1,159 Slightly higher year-over-year, reflecting continued investments in innovation and product advancements General and Administrative 1,055 5,426 Down year-over-year driven by a reversal of royalty expenses and a recovery of credit losses(1) Total Operating Expense 11,086 13,105 Significant reductions in G&A, partially offset by higher selling and marketing investments Operating Income / (Loss) $7,111 $(168) Reflects higher net sales, improved gross margins and lower total operating expense (1) In Q4 2024, G&A was reduced by the reversal of royalties and fees following a supplemental agreement with Dartmouth, which waived certain obligations under the exclusive license agreements. Additionally, the recovery of credit losses from a legal settlement with Elysium Health, LLC reversed a bad debt write-off from 2019.

11 Adjusted EBITDA Summary Full year 2024 Adjusted EBITDA reached $8.5 million, up $6.6 million YoY, driven by higher net income, partially offset by lower share-based compensation expense, reversed royalties & fees and recovered credit losses. ChromaDex Corporation and Subsidiaries Reconciliation of Non-GAAP Finanical Measures (In thousands) Three Months Ended FY 2023 Three Months Ended FY 2024Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Net income (loss), as reported $ (1,902) $ (2,191) $ (959) $ 114 $ (4,938) $ (492) $ (15) $ 1,878 $ 7,179 $ 8,550 Adjustments Interest (income) expense (66) (125) (188) (282) (661) (239) (241) (276) (373) (1,129) Provision for income taxes — — — — — — — — 305 305 Depreciation 228 232 233 177 870 178 170 164 151 663 Amortization of intangibles 41 39 39 39 158 38 37 38 38 151 Noncash lease expense 171 173 176 157 677 174 163 164 169 670 Share-based compensation 1,273 1,324 1,117 1,037 4,751 984 1,185 735 752 3,656 Severance and restructuring 186 766 86 5 1,043 27 276 185 (4) 484 Reversal of previously accrued royalties and license maintenance fees (1) — — — — — — — — (3,521) (3,521) Recovery of credit losses related to legal settlement (2) — — — — — — — — (1,325) (1,325) Adjusted EBITDA $ (69) $ 218 $ 504 $ 1,247 $ 1,900 $ 670 $ 1,575 $ 2,888 $ 3,371 $ 8,504 (1) The reversal of royalties and fees is due to a supplemental agreement with Dartmouth, which waived certain obligations under the exclusive license agreements. (2) The recovery of credit losses stems from the 2024 legal settlement with Elysium Health, LLC, reversing a bad debt write-off from 2019.

12 Q4 2024 Operating Loss vs Q4 2023 (0.2) (2.2) (0.2) 4.8 4.1 0.4 0.2 0.2 7.1 Q4 2023 Operating Loss Sales & Marketing Research & Development Volume Other G&A (1) Gross Margin Improvement Equity Comp (G&A) Legal Q4 2024 Operating Income (4.0) MM (3.0) MM (2.0) MM (1.0) MM 0.0 MM 1.0 MM 2.0 MM 3.0 MM 4.0 MM 5.0 MM 6.0 MM 7.0 MM 8.0 MM (in millions) +$9.7MM $(2.4)MM (1) Includes the reversal of royalties and fees related to a supplemental agreement with Dartmouth, which waived certain obligations under the exclusive license agreements totaling $3.5 million and the recovery of approximately $1.3 million in credit losses related to the legal settlement with Elysium Health, LLC.

13 Balance Sheet Highlights Highlights effective execution of strategic priorities, resulting in a stronger balance sheet with improved liquidity, reduced inventory, and enhanced receivables, all while maintaining disciplined cost management to support long-term growth. (in thousands) 12/31/23 3/31/24 6/30/24 9/30/24 12/31/24 Key Drivers (December 31 2024 vs 2023) Cash $27,325 $27,565 $27,885 $32,398 $44,660 Up $17.3 million driven by cash generated from operating activities and proceeds from stock option exercises Inventory 14,525 12,495 11,511 10,544 9,192 Down $5.3 million driven by increased sales and a streamlined inventory approach Trade Receivables 5,234 6,604 7,818 7,096 7,768 Up $2.5 million driven by increased sales, changes in customer sales mix, and the timing of collections Accrued Expenses 9,493 10,465 8,621 9,592 7,817 Down $1.7 million driven by the reversal of previously accrued royalties (1), partially offset by changes in and timing of expenses Accounts Payable 10,232 7,899 8,105 6,903 8,526 Down $1.7 million driven by changes in inventory and other expenses and the timing of disbursements Equity $28,456 $28,951 $30,718 $34,369 $46,094 Down $17.6 million driven by net income, share-based compensation and proceeds from stock option exercises (1) The reversal of royalties and fees is due to a supplemental agreement with Dartmouth, which waived certain obligations under the exclusive license agreements.

14 Cash Flow Highlights (in thousands) FY 2023 3/31/24 6/30/24 9/30/24 12/31/24 FY 2024 Net Income (Loss) $(4,938) $(492) $(15) $1,878 $7,179 $8,550 Working Capital 5,206 (643) (1,837) 1,235 5,111 3,866 Cash From / (Used for) Operations 7,117 295 (264) 3,495 8,583 12,109 Cash Used for Investing (143) (41) (12) (21) (69) (143) Cash From / (Used for) Financing (90) (14) 596 (1) 1,039 (2) 3,748 (3) 5,369 (4) Net Increase / (Decrease) in Cash $6,884 $240 $320 $4,513 $12,262 $17,335 Ending Cash Balance $27,325 $27,565 $27,885 $32,398 $44,660 $44,660 Strong management of working capital, coupled with impressive top- and bottom-line growth and stock option exercises, drove positive cash flow, ending the year with $44.7 million in cash and no debt. 1. Includes $0.6 million in proceeds from the exercise of stock options. 2. Includes $1.0 million in proceeds from the exercise of stock options. 3. Includes $3.8 million in proceeds from the exercise of stock options. 4. Includes $5.4 million in proceeds from the exercise of stock options.

15 2024 Full Year Outlook Recap (in thousands) 2023 Actual 2024 Outlook (1) 2024 Actual Comments Achieved?(2) Net Sales $83,570 Approximately 15% growth YoY $99,597 Total net sales grew by +19% ü Gross Margin % (as a % of net sales) 60.8% Slight improvement YoY 61.8% Improved 100 bps ü Selling, Marketing & Advertising (as a % of net sales) 31.6% Up in absolute dollars and stable as a % of net sales YoY 29.6% Up $3.0 million Improved 200 bps as a % of net sales ü Research & Development $4,958 Up in absolute dollars YoY $6,016 Up $1.1 million ü General & Administrative $24,983 Down $1.5 million in absolute dollars YoY $18,375 Down $6.6 million ü Adjusted EBITDA $1,900 Outlook not provided $8,504 Improvement of $6.6 million N/A Exceeded financial outlook, outperforming targets across all key performance metrics, reflecting disciplined execution and sustained momentum. (1) 2024 Outlook as presented on Q3 2024 earnings call. (2) Compares 2024 actuals to 2024 Outlook.

16 (in thousands) 2024 Actual 2025 Full Year Outlook Key Drivers Net Sales $99,597 Approximately 18% growth YoY • Includes growth from e-commerce business and recurring revenues from established partnerships. • Includes revenues from new partnerships, and revenue growth in the pharmaceutical grade ingredient segment. Gross Margin % (as a % of net sales) 61.8% Slight improvement YoY • Margin accretion from sales mix, scale, and continued supply chain optimization and cost savings initiatives. Selling, Marketing & Advertising $29,469 Up in absolute dollars and stable as a % of net sales YoY (29.6% of net sales in FY 2024) • Focused and optimized investments to drive brand awareness, and increase customer acquisition and retention while maintaining efficiency. Research & Development $6,016 Up in absolute dollars and stable as a % of net sales YoY (6.0% of net sales in FY 2024) • Increased investment in external research to support new product development, and continued NAD precursor development. General & Administrative(1) $18,375 Up $5.0 to $6.0 million in absolute dollars YoY • Increased infrastructure investments and legal expense to support growth and strategic business initiatives and the absence of 2024 royalty expense reversals. 2025 Financial Outlook Solid revenue growth in 2025, with focused investments to support brand building initiatives along with R&D investments to drive future innovation and growth. Continued focus on top- and bottom-line. (1) FY 2024 actual G&A includes the reversal of royalties and fees related to a supplemental agreement with Dartmouth, which waived certain obligations under the exclusive license agreements totaling $3.5 million and the recovery of approximately $1.3 million in credit losses related to the legal settlement with Elysium Health, LLC.

The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019) The Science 17

18 Scientific Advisory Board Charles Brenner, Ph.D. Alfred E Mann Family Foundation Chair, Department of Diabetes & Cancer Metabolism City of Hope World's Foremost Authority on NAD Metabolism Roger Kornberg, Ph.D. Chairman Professor of Structural Biology Stanford University Nobel Prize Winner, Chemistry, 2006 Rudolph Tanzi, Ph.D. Kennedy Professor of Neurology Harvard University Leading Alzheimer's Researcher, TIME 100 Most Influential 2015 Dr. Bruce German Chairman of Food, Nutrition, & Health University of California, Davis Leader in Food, Nutrition, & Wellness Innovation Professor Sir John Walker, Ph.D. Emeritus Director, MRC Mitochondrial Biology University of Cambridge Nobel Prize Winner, Chemistry, 1997 Brunie H. Felding, Ph.D. Associate Professor of Molecular Medicine Scripps Research Institute Renowned Breast Cancer Researcher focused on NAD+ supplementation Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc. Professor in Genome Instability and Neurodegeneration, Department of Cellular and Molecular Medicine, University of Copenhagen. One of the world’s most published researchers on aging and neurodegenerative disease NOBEL PRIZE WINNERS | CHEMISTRY

19 Clinical Studies on Niagen® in Multiple Health Areas Note: highlighted achievements in duration, participation and dosage only consider completed studies. Status of clinical studies presented as of 2/18/2025.

20 Contact Info: Ben Shamsian Lytham Partners T: +1(646) 829-9701 Shamsian@LythamPartners.com www.ChromaDex.com Where to purchase Tru Niagen® TruNiagen.com Find Health Clinics Offering Niagen® Plus NiagenPlus.com

Cover	Mar. 04, 2025
Cover [Abstract]
Document Type	8-K
Document Period End Date	Mar. 04, 2025
Entity Registrant Name	CHROMADEX CORPORATION
Entity Incorporation, State or Country Code	DE
Entity File Number	001-37752
Entity Tax Identification Number	26-2940963
Entity Address, Address Line One	10900 Wilshire Blvd.
Entity Address, Address Line Two	Suite 600
Entity Address, City or Town	Los Angeles
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90024
City Area Code	(310)
Local Phone Number	388-6706
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	CDXC
Entity Emerging Growth Company	false
Entity Central Index Key	0001386570
Amendment Flag	false